Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Inducing labor at 39 weeks versus later induction or waiting in low‑risk pregnancies in China.

Official title: Labor Induction in Low-risk Women at 39 Weeks of Gestation: A Randomized Trial in China

Run by Women's Hospital School Of Medicine Zhejiang University · NCT07082530 · Data updated 2026-11-12

This study will test whether inducing labor at 39 weeks, compared with inducing at 41 weeks or waiting, reduces cesarean deliveries and improves outcomes for low‑risk pregnant women in China.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment1074 (estimated)
SponsorWomen's Hospital School Of Medicine Zhejiang University
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedJuly 30, 2025
Main results expectedDecember 30, 2027
Study endsJune 30, 2028
Registry record updatedJuly 30, 2026
Trial IDNCT07082530 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are low‑risk pregnant women aged 18 or older with a singleton pregnancy (or twins reduced to singleton before 14 weeks), reliable dating, desire and eligibility for vaginal birth, and who are between 38 weeks 4 days and 39 weeks 3 days at enrollment.

Probably not a fit

Women with planned cesarean delivery, contraindications to induction or vaginal birth, abnormal placentation, ruptured membranes at enrollment, or unreliable gestational dating are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial enrolls low‑risk pregnant women at 38 weeks 4 days to 39 weeks 3 days and randomly assigns them to induction at 39 weeks, induction at 41 weeks, or expectant management. The primary outcome is cesarean delivery rate, with collection of other maternal and neonatal outcomes to compare safety and benefits across groups. Cord blood samples will undergo multi‑omics analyses (including metabolomics and proteomics) to identify biological markers associated with outcomes. The trial is led by the Women's Hospital, School of Medicine, Zhejiang University at its Hangzhou site.

Why it matters

Potential benefit: If successful, it could identify a timing for induction that lowers cesarean rates and improves maternal and newborn health in the Chinese population.

How similar studies have gone: A large U.S. trial (ARRIVE) found that elective induction at 39 weeks reduced cesarean rates, while similar international trials are ongoing and Chinese‑specific evidence is currently lacking.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years.
2. Singleton pregnancy or twin pregnancy reduced to singleton before 14 weeks.
3. Gestational age between 38 weeks 4 days or 38 weeks 6 days at randomization.
4. Eligible for vaginal delivery with a desire for vaginal birth.
5. Reliable gestational age determination.
6. Maternal and fetal conditions assessed as low-risk by at least two senior obstetricians, with no indications requiring delivery before 41 weeks.
7. Ability to understand study information and provide informed consent.

Exclusion Criteria:

1. First-trimester ultrasound estimate \>13 weeks 6 days.
2. Planned induction before 41 weeks.
3. Planned cesarean delivery or contraindications to vaginal delivery.
4. Already delivered, in labor, or ruptured membranes at enrollment.
5. Placenta previa, vasa previa, placenta accreta, or placental abruption.
6. Contraindications to induction (e.g., cervical cancer, history of uterine rupture, genital tract malformations, abnormal fetal position, cord prolapse).
7. Active vaginal bleeding exceeding spotting.
8. History of cesarean delivery or uterine/cervical surgery.
9. Cervical cerclage during this pregnancy.
10. Maternal conditions not suitable for expectant management beyond 39 weeks (e.g., pregestational diabetes, gestational diabetes requiring insulin, hypertensive disorders, intrahepatic cholestasis of pregnancy).
11. Fetal conditions not suitable for expectant management beyond 39 weeks (e.g., fetal death, major anomalies, growth restriction, macrosomia, anemia, oligohydramnios, polyhydramnios).
12. Maternal infections or positive screenings for sexually transmitted pathogens or group B Streptococcus.
13. Planned delivery at a non-study facility.
14. Participation in another intervention study affecting delivery management.

Where it's running

  • Women's Hospital School of Medicine Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Dan Zhang, Ph. D. — Key Laboratory of Reproductive Genetics, Women's Hospital, Zhejiang University School of Medicine
  • Study coordinator: Huajing Gao, MD Candidate
  • Email: huajingg@zju.edu.cn
  • Phone: 86+18867114750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.